FdaApplication
NDA 209637
Identifiers
- fda_app_no: NDA209637
Properties
| Property | Value |
|---|---|
| applicant_name | NOVO NORDISK INC |
| application_type | NDA |
| approval_date | 2017-12-05 |
Products (7)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OZEMPIC | SEMAGLUTIDE | 0.5MG/0.5ML (0.5MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| OZEMPIC | SEMAGLUTIDE | 2MG/1.5ML (1.34MG/ML) | SOLUTION;SUBCUTANEOUS |
| OZEMPIC | SEMAGLUTIDE | 1MG/0.5ML (1MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| OZEMPIC | SEMAGLUTIDE | 0.25MG/0.5ML (0.25MG/0.5ML) | SOLUTION;SUBCUTANEOUS |
| OZEMPIC | SEMAGLUTIDE | 8MG/3ML (2.68MG/ML) | SOLUTION;SUBCUTANEOUS |
| OZEMPIC | SEMAGLUTIDE | 2MG/3ML (0.68MG/ML) | SOLUTION;SUBCUTANEOUS |
| OZEMPIC | SEMAGLUTIDE | 4MG/3ML (1.34MG/ML) | SOLUTION;SUBCUTANEOUS |
7 products